Edited by Peter Hillerberg1 min readStories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
News of fresh healthcare pricing rules pushed by Robert F. Kennedy Jr. drew the most active bearish options flow in the S&P 500 this week. UnitedHealth Group, CVS Health and The Cigna Group all appeared in elevated negative-bet rankings. Healthcare pricing transparency proposals tend to hit managed care names hardest, and options markets have been pricing in downside risk accordingly.
UnitedHealth, with a $334 billion market cap and an RSI of 40.4, sits in technically oversold territory. Its Q3 earnings call is imminent. CVS carries the lowest short score of the three at 29.5. Analysts see 34% upside from current levels. trades down 1.7% year-to-date. Its short score stands at 34.5.
On the bullish side, Micron Technology sits at the top of positive options bets in the S&P 500. The stock is up 277% year-to-date. It carries the highest ORTEX stock score in the index at 98.74. NVIDIA and Advanced Micro Devices also feature near the top of positive options flow. Chip stocks have seen call-side activity rebound after last week's South Korea-led tech selloff.
Outside the index, Wolfspeed stands out. Its short score is 78.1 and days to cover sits at 11.3. The stock has doubled year-to-date. Options-aware traders watching this name face a crowded short base meeting a strong price trend, a classic squeeze setup.
Lumentum Holdings appeared across both positive and negative options bets. Its Q4 earnings call is approaching. The stock is up 194% year-to-date. That dual-sided flow suggests traders are buying straddles rather than placing a directional bet.
Medicare Advantage penetration has risen for six consecutive months to 51.1% as of June 2026, per ORTEX Alt Data. With 36.1 million beneficiaries now enrolled, any pricing intervention targeting managed care plans carries sector-wide implications. The options market is already reflecting that risk.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
